SynthesisPloS one2017
Prognostic value of pretreatment serum carbohydrate antigen 19-9 level in patients with colorectal cancer: A meta-analysis.
Synthesis in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Ten-Year Outcomes in Colorectal Cancer-Competing Risks and Patient Vulnerability: A Prospective Multicenter Observational Study.Journal of clinical medicine · 2026Article
- Prognostic Role of CA19-9 in Patients Undergoing Hepatectomy for Colorectal Liver Metastases.Cancers · 2026Review
- Raised Serum Tumour Markers Predict Incomplete Cytoreduction, Disease-Free and Overall Survival in Patients with Colorectal Peritoneal Metastases Treated by Cytoreductive Surgery and HIPEC.Annals of surgical oncology · 2026Article
- Influencing factors of prognosis in HIV infected individuals undergoing surgical treatment for colorectal cancer.Frontiers in oncology · 2026Article
- Predictive value of tumor marker index for pathological complete response following neoadjuvant chemoradiotherapy in locally advanced rectal cancer.World journal of surgical oncology · 2025Article
- Prediction of regional lymph node metastasis in rectal cancer: a novel model based on transrectal contrast-enhanced ultrasound.Discover oncology · 2025Article
- Article
- Population-based colorectal cancer risk prediction using a SHAP-enhanced LightGBM model.Frontiers in oncology · 2025Article
- Stage IV Colorectal Cancer Management and Treatment.Journal of clinical medicine · 2023Review
- Is CA19-9 effective in predicting chemotherapeutic response in patients with synchronous liver metastases with colorectal cancer?World journal of gastroenterology · 2022Article
- Circulating syndecan-1 and glypican-4 predict 12-month survival in metastatic colorectal cancer patients.Frontiers in oncology · 2022Article
- Comparison of guidelines on rectal cancer: exception proves the rule?Gastroenterology report · 2021Review
- Predictive factors associated with relapse of stage II/III colon cancer treated with peroral anti-cancer agents in the adjuvant setting.Molecular and clinical oncology · 2021Article
- Diagnostic and Prognostic Value of CEA and CA19-9 in Colorectal Cancer.Diseases (Basel, Switzerland) · 2021Article
- Carbohydrate antigen 19-9 - tumor marker: Past, present, and future.World journal of gastrointestinal surgery · 2020Review
- Markers of metastatic colorectal cancer.Przeglad gastroenterologiczny · 2020Review
- Esophageal, gastric and colorectal cancers: Looking beyond classical serological biomarkers towards glycoproteomics-assisted precision oncology.Theranostics · 2020Review
- A prognostic index for colorectal cancer based on preoperative absolute lymphocyte, monocyte, and neutrophil counts.Surgery today · 2019Article
- High Serum CA19-9 Concentration Predicts Poor Prognosis in Elderly Patients with Stage IV Colorectal Cancer.Gastrointestinal tumors · 2019Article
- Diagnostic value of elevated serum carbohydrate antigen 199 level in acute cholangitis secondary to choledocholithiasis.World journal of clinical cases · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCarbohydrate antigen 19-9 (CA 19-9) is one of the most frequently used tumor markers for gastrointestinal cancer, particularly for diagnostic purposes. However, its value in predicting prognosis remains controversial. In this study, we sought to clarify this by conducting a meta-analysis of relevant studies.
methodsWe systematically searched several databases, including PubMed, EMBASE and Web of Science for articles pertaining to the relationship between pretreatment serum CA 19-9 levels and prognosis in patients with colorectal cancer (CRC). The reported hazard ratios (HR) of overall survival (OS), disease-free survival (DFS), pooled progression-free survival (PFS) and recurrence-free survival (RFS) in the analyzed studies were compared by fixed effects/random effects models.
resultsSeventeen studies involving 6434 patients with CRC were included in our meta-analysis. A comprehensive analysis of the collected data revealed that high serum CA 19-9 levels before treatment were significantly associated with poor OS (HR: 1.58, 95% CI: 1.36-1.83, P<0.001), DFS (HR: 1.71, 95% CI: 1.38-2.13, P<0.001), PFS (HR: 1.30,95%CI:0.93-1.82, P = 0.121) and RFS (HR: 1.43, 95% CI: 1.11-1.83, P = 0.006). This association between high pretreatment serum CA 19-9 levels and poor survival held true across different geographical regions, analysis types, methods used for HR determination, sample size, and treatment methods.
conclusionsThe results of this study indicate that pretreatment serum CA 19-9 level can be used as a prognostic indicator for patients with CRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.